NR3C2 and hypertensive disorder: MR antagonists have already been shown to be the most effective add-on therapy in low-renin resistant hypertension [98], however, the adoption of MR antagonists as effective anti-hypertensives that can be used early in the treatment of hypertension using a renin- and aldosterone-based phenotyping approach has not been evaluated with sufficient evidence for widespread recommendation.